from the Medical University of South Carolina (MUSC) for the connexin-technology platform and intellectual properties of a portfolio of peptides capable of modulating junctional proteins that are critical for inter-cellular communication. A Phase I human clinical trial demonstrated safety and efficacy of a lead peptide generated from the technology platform. The Company is now advancing GranexinTM Gel, a topical formulation of the lead peptide, through three Phase II human clinical trials for scar reduction and treatment of chronic wounds.